BACKGROUND: Cardiovascular disease is the leading cause of mortality in type 1 diabetes mellitus (T1DM) and relates strongly to insulin resistance (IR). Lean and obese adolescents with T1DM have marked IR. Metformin improves surrogate markers of IR in T1DM, but its effect on directly measured IR and vascular health in youth with T1DM is unclear. We hypothesized that adolescents with T1DM have impaired vascular function and that metformin improves this IR and vascular dysfunction.
RESULTS:
Forty-eight adolescents with T1DM who were 12 to 21 years of age (40% body mass index [BMI] ≥90th percentile; 56% female) and 24 nondiabetic control participants of similar age, BMI, and sex distribution were enrolled. Adolescents with T1DM demonstrated impaired aortic health compared with control participants, including elevated AA and descending aorta pulse wave velocity, reduced AA and descending aorta relative area change, and elevated AA and descending aorta WSS MAX and WSS TA . Adolescents with T1DM in the metformin versus placebo group had improved glucose infusion rate/insulin (12. ]/μIU/μL, P=0.02). The metformin group had reduced AA WSS MAX (−0.3±0.4 dyne/cm 2 versus 1.5±0.5 dyne/cm T he incidence of youth-onset type 1 diabetes mellitus (T1DM) is increasing worldwide, 1 translating to a lifetime of exposure and increased risk for early death resulting from cardiovascular disease (CVD). Vascular dysfunction starts early after the onset of T1DM and relates to metabolic risk factors, including glycemic control, blood pressure (BP), and dyslipidemia. 2 Although control of hyperglycemia, hypertension, and hyperlipidemia is beneficial, normalization of these risk factors only partially protects against CVD. 2 In fact, clinical trials focused on mitigating these traditional risk factors have yielded disappointing results. The recently published AdDIT trial (Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial) demonstrated that use of an angiotensin-converting enzyme inhibitor and a statin over 2 to 4 years failed to change carotid intima-media thickness (cIMT) and other CVD risk markers in youth with T1DM. 3 Thus, evaluating alternative therapeutic targets to impede the development of CVD remains a public health priority. Using gold-standard techniques, we and others have demonstrated that insulin resistance (IR) is a prominent feature of T1DM in adolescents 4, 5 and adults, 6 even those of normal weight, and that evidence of cardiac and vascular dysfunction is already present during adolescence in T1DM. 4, 7, 8 Moreover, IR has been increasingly recognized to confer higher risk for a more atherogenic lipoprotein profile 9, 10 and microvascular and macrovascular complications in youth with T1DM 11 and adults. 12, 13 Furthermore, the DCCT (Diabetes Control and Complications Trial) emphasized that intensive glycemic control reduces, but does not eliminate, T1DM complications and was associated with weight gain in a subset of participants, along with worsening lipid profiles, BP, central adiposity, and inflammation, all of which may negate positive effects of improved glycohemoglobin (HbA 1c ).
14 Central aortic stiffness is an early predictor of overt CVD in adults with T1DM and type 2 diabetes mellitus (T2DM) 15, 16 and is reported in children and young adults with T1DM. [17] [18] [19] However, most previous studies applied tonometric-based methods, which can underestimate central aortic stiffness by disregarding aortic wave reflections and making assumptions about intravascular length and homogeneous aortic wall morphology. 20 Phase-contrast magnetic resonance imaging (MRI)-derived pulse wave velocity (PWV) from the flow-area method offers more specific comparison of aortic extrinsic properties. 21 Phase-contrast MRI is also a technique that can noninvasively and simultaneously provide multiple direct measures of aortic health and may be more sensitive to early cardiovascular changes in T1DM than traditional vascular measures. Phase-contrast MRI has not yet been comprehensively investigated in this population.
Metformin has been shown to reduce CVD risk and to improve body composition in adults with T2DM. 22 Similarly, we previously demonstrated that metformin lowered the daily insulin dose in overweight/obese adolescents with T1DM and in adolescents with T1DM with high HbA 1c , implying improved insulin sensitivity. 23, 24 However, these studies did not evaluate whether metformin directly improves insulin sensitivity or CVD in T1DM or whether its effects are different in normalweight versus obese patients. Normal-weight patients are important to consider because both normal-weight and obese adolescents with T1DM are significantly insulin resistant compared with body mass index (BMI)-matched normoglycemic peers, yet they have a unique phenotype that differs from that of youth with T2DM. 4 Accordingly, we had the following objectives: to assess MRI-based aortic health in adolescents with T1DM versus nondiabetic control participants of similar age, sex, and BMI distribution and to perform a 3-month, placebo-controlled, double-blinded, randomized trial to
Clinical Perspective
What Is New?
• We detected early signs of cardiovascular disease with magnetic resonance imaging in adolescents with type 1 diabetes mellitus (T1DM) compared with control participants. • Insulin resistance is increasingly being recognized as a contributor to the excess risk of cardiovascular disease in T1DM.
• We found that 3 months of metformin therapy improved insulin sensitivity, assessed by a goldstandard hyperinsulinemic euglycemic clamp, in both normal-weight and obese adolescents with T1DM.
• Moreover, metformin improved carotid intimamedia thickness and aortic wall shear stress and stiffness.
What Are the Clinical Implications?
• Glycemic control is most difficult during adolescence.
• Adolescents with T1DM are also more insulin resistant than their peers, increasing their risk for cardiovascular disease.
• Insulin resistance is further worsened by the rising obesity prevalence in T1DM, creating a need for adjunctive therapies in T1DM to lower cardiovascular disease risk.
• We demonstrated that metformin, a safe oral medication, can improve insulin resistance, body mass index, and fat mass in adolescents with T1DM.
• We were also able to detect improvements in vascular health after 3 months of metformin.
• These effects of metformin suggest potential cardiovascular disease risk protection, arguing for future, longer-term trials.
Circulation. 
METHODS
The data, analytical methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure and are available by contacting the corresponding author. This study was approved by the Colorado Multiple Institutional Review Board, and all participants and guardians provided written informed assent and consent as appropriate for age. An Investigational New Drug exemption was obtained from the US Food and Drug Administration for the use of metformin. In addition to the study investigators and Colorado Multiple Institutional Review Board, an independent safety officer monitored the study.
Participants and Study Design
As part of the EMERALD study (Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes; ClinicalTrials.gov identifier: NCT01808690), 52 adolescents with T1DM were recruited from the Barbara Davis Center for Childhood Diabetes and from private endocrinology practices between 2013 and 2017. Inclusion criteria included age of 12 to 21 years, Tanner stage 1 or greater, diabetes duration of ≥1 year, and T1DM defined as diabetes by American Diabetes Association criteria, ≥1 diabetes mellitus-associated autoantibody, and insulin requirement since diagnosis. Exclusions included resting BP >140/90 mm Hg, hemoglobin <9 g/L, serum creatinine >106 µmol/L, HbA 1c >108 mmol/mol, smoking, medications affecting insulin sensitivity (oral steroids, immunosuppressants, noninsulin antidiabetic agents, atypical antipsychotics), antihypertensive medications, pregnancy, breastfeeding, implanted metal, weight >136 kg, BMI <5th percentile, severe illness or diabetic ketoacidosis within 60 days, inability to tolerate ≥500 mg metformin twice per day, and plans to alter amount of exercise, mode of insulin delivery, or diet during the study. Contraceptive medications were not excluded. Urine pregnancy tests were performed in female participants before randomization and hyperinsulinemic euglycemic clamp visits.
After an initial screening visit, 48 eligible adolescents with T1DM underwent a baseline comprehensive evaluation of insulin sensitivity, body composition, and vascular health (see below) at Children's Hospital Colorado and were then randomized to 3 months of metformin or an identical-appearing placebo. All study measures were then repeated in the adolescents with T1DM after completion of the 3-month intervention. Twenty-four nondiabetic control participants of similar age, BMI, and sex distribution also underwent an identical comprehensive MRI of the ascending aorta (AA) and descending aorta (DA) for comparison.
In the T1DM group, the cardiovascular assessment and dual-energy x-ray absorptiometry and MRI examinations were performed on 1 day, followed by an admission that evening with an overnight insulin drip to control glycemia. If the participant was on insulin injections, the last long-acting insulin dose was given 24 hours before the overnight insulin drip was started. The following morning, fasting laboratories were drawn, followed by a hyperinsulinemic euglycemic clamp to measure insulin sensitivity. All assessments were performed in the morning after the participant fasted for at least 10 hours, in the early follicular phase for menstruating female participants when possible, and preceded by 3 days of no caffeine or strenuous physical activity. Visits were rescheduled if severe hypoglycemia occurred in the prior 24 hours or if hyperglycemia with large ketones or signs of acute metabolic decompensation were present. Participants gave a correction bolus of insulin at home if their waking morning blood sugar was above their target range to minimize hyperglycemia on arrival. Blood glucose was checked again on arrival, treated if low, and documented to have resolved before assessments were initiated.
Anthropometrics
BMI z score was calculated from BMI, sex, and age by the least mean squares method using 2000 Centers for Disease Control and Prevention growth charts. Body composition by dual-energy x-ray absorptiometry (Hologic) was performed to determine fat mass and lean mass. 
Cardiovascular Assessments
BP was measured with a manual cuff immediately before MRI evaluation with the pressure oscillometer technique (Invivo, model 1400 MRI). BP and heart rate were taken seated after at least 5 minutes of rest. cIMT was assessed with ultrasound as previously described. 25 Briefly, far-wall cIMT was measured from a longitudinal 2-dimensional B-mode image obtained with a Vivid 7 (General Electric, Waukesha, WI) ultrasound system and analyzed with Vascular Analysis Tools software version 5.0 (MIA, Coralville, IA). cIMT was defined as the distance from the leading edge of the media-adventitia interface of the near wall to the media-adventitia interface of the far wall. Lumen diameter was measured as the distance between the vessel far-wall boundary (corresponding to the interface between the lumen and intima) and a near-wall boundary (corresponding to the interface of the adventitia and media). The average of 5 separate lumen and intima-media thickness measurements was used for analysis. All images were coded by number, blinded to group assignment, and analyzed by a single cardiologist with extensive experience in arterial imaging (U.T.). The Dynapulse 5200A Pathway system (PulseMetric, Inc, San Diego, CA), a noninvasive portable system, was used to measure brachial artery distensibility, with pulse waveform analysis of arterial pressure signals obtained from a sphygmomanometer.
26

Cardiovascular MRI
All participants underwent MRI evaluation with a 3-T magnet system (Skyra, Siemens, Erlangen, Germany) using a 32-channel coil. A free-breathing phase-contrast sequence was applied with cartesian encoding and retrospective sorting (repetition time, 14-28 milliseconds; 30-50 phases; echo time, 2.2-3.5 milliseconds; matrix: 160×256; flip angle, 25°)
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with 100% k-space sampling and no further temporal interpolation. Depending on participant size and field of view (128-225×210-360 mm), the cross-sectional pixel resolution was 0.82×0.82 to 1.56×1.56 mm 2 with a slice thickness of 5 mm. Phase contrast acquisition time for each plane varied per heart rate, between 2 and 3 minutes. Velocity-encoding values were adjusted according to the maximum velocities encountered during scout sequences to avoid aliasing artifact (typically 100-250 cm/s).
This phase-contrast sequence was applied orthogonally to the AA at approximately 1 cm above the sinotubular junction; a plane that also corresponded to an orthogonal plane across the DA, ≈3 to 5 cm below the origin of the left subclavian artery. Both magnitude (tissue intensity) and phase-velocity maps were obtained, and raw data were transferred to an offline processing system, MatLab (Mathworks, Inc, Natick, MA), to determine the PWV, relative area change, and wall shear stress (WSS). Using the flow-area (dQ/dA) method, we generated flow and area waveforms from time frame-segmented respective phase and magnitude images. 20, 27 Flowarea diagrams assessed regional PWV by computing the dQ/ dA slope from early systolic data points. Central aortic distensibility was measured from the relative area change ([maximum area−minimum area]/maximum area)×100%). WSS was calculated from segmented phase and magnitude images as described previously using an 8-point model to calculate through-plane WSS from the shear curve, yielding maximum systolic WSS (WSS MAX ) and time-averaged WSS (WSS TA ).
Insulin Sensitivity
Participants with T1DM were admitted to the inpatient Clinical and Translational Research Center (CTRC) for 12 hours of overnight monitored fasting and bed rest, after a fixed-macronutrient (55% carbohydrate, 30% fat, 15% protein, no caffeine, no regular soda), weight-maintenance meal provided and labeled for carbohydrate counting with shortacting insulin by the CTRC metabolic kitchen. Subcutaneous insulin was then replaced with a variable-rate overnight intravenous insulin infusion to gradually normalize glucose as previously described. 4, 28 The next morning, a multiphase hyperinsulinemic euglycemic clamp (insulin doses of 10 mU·m −2 ·min −1 for 60 minutes, 16 mU·m −2 ·min −1 for 90 minutes, 80 mU·m −2 ·min −1 insulin for 120 minutes, paired with a variable rate of 20% dextrose) was performed as previously described to quantify insulin sensitivity. 4, 29 One intravenous was used for infusion of dextrose and insulin, and the contralateral, heated, arterialized intravenous was used for blood sampling and bedside monitoring of blood glucose (BG) every 5 minutes with a steady-state goal BG of 5.3 mmol/L. Glucose infusion rate in milligrams per kilogram per minute and milligrams per lean kilogram per minute was calculated during steady state of the final stage. 29 Insulin sensitivity was calculated as glucose infusion rate/insulin (M/I), where I is the insulin concentration at steady state.
Laboratory Measures
Fasting serum laboratories were drawn in the morning before the hyperinsulinemic clamp during normoglycemia, including: HbA 1c , aspartate aminotransferase, alanine aminotransferase, lipid panel, glucose, insulin, and creatinine. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were assessed via enzymatic assays (Beckman Coulter); low-density lipoprotein cholesterol (LDL-C) levels were calculated with the Friedewald equation. HbA 1c was measured by Diabetes Control and Complications Trial-calibrated ionexchange high-performance liquid chromatography (Bio-Rad Laboratories, Hercules, CA). Other laboratory tests were performed by standard methods in the CTRC laboratory.
Intervention
After completion of baseline assessments, participants with T1DM were randomized 1:1 by the Children's Hospital Colorado research pharmacist in a double-blinded fashion using the Microsoft Excel randomization function to 3 months of active metformin or identical-appearing placebo (compounded by Belmar Compounding Pharmacy, Lakewood, CO). The research pharmacist maintained the blinding code and assigned participants to interventions. Blinded investigators enrolled and followed up the participants, who were also blinded. Randomization was stratified by HbA 1c above or below 69 mmol/mol and BMI above or below the 85th percentile. Study medication was titrated to a final dose of 1000 mg twice daily over a period of 4 weeks (minimum dose required was 1000 mg/d). After the 12-week treatment phase, all participants with T1DM underwent repeat outcome assessments identical to the baseline assessments.
Throughout the study, participants were asked to check their home BG ≥4 times per day and urine ketones if BG >16.7 mmol/L on ≥3 consecutive readings and to contact the study staff for assistance for large urine ketones, ≥2 BG <3.6 mmol/L in any week, hypoglycemia requiring assistance, or other concerns. Participants adjusted insulin doses as routinely recommended by their care provider. An interim phone call occurred weekly during metformin/placebo titration, at 10 weeks, and as needed; in-person visits occurred at 6 and 12 weeks to assess BG, insulin dose, pill count, side effects, hemoglobin, alanine aminotransferase, aspartate aminotransferase, and serum creatinine. Adverse events were queried at all scheduled and unscheduled phone calls and visits. The primary predefined severe adverse events included lactic acidosis, anemia, severe hypoglycemia, and diabetic ketoacidosis. Gastrointestinal symptoms were also evaluated, as well as changes in serum creatinine, aspartate aminotransferase, and alanine aminotransferase and unanticipated adverse events.
Power Calculations
Power calculations were based on data from a small study in youth with poorly controlled T1DM, 30 which reported a significant increase in M/I in the 11 participants treated with metformin. On the basis of the effect size reported in that study, a sample size of 25 per group and an α of 0.05 provided us with 93% power to detect a difference of 1 SD in the primary outcome of M/I.
Statistical Analyses
Analyses were performed with SAS (version 9.4 or higher; SAS Institute, Cary, NC). Variables were checked for the distributional assumption of normality with normal plots, in ORIGINAL RESEARCH ARTICLE addition to Kolmogorov-Smirnov and Shapiro-Wilks tests. Variables that were skewed were natural log transformed, and skewed variables that included negative values were log-modulus transformed for the analyses. Demographic and clinical characteristics in adolescents with and without T1DM and in the metformin and placebo groups were compared by use of t tests for normally distributed continuous variables and χ 2 tests for categorical variables. General linear regression models were used to determine the effect of metformin versus placebo therapy on the primary outcome of M/I per 1 kg and M/I per 1 lean kg, secondary outcomes of near-and far-wall cIMT, brachial distensibility, MRI-derived aortic PWV and WSS, and tertiary measures of body composition, HbA 1c , LDL-C, and BP. The change in the outcomes from baseline to 3 months was the dependent variable in the models, and all models were adjusted for the baseline values of the dependent variables. We also fitted multivariable models, which included sex, pubertal status, and change in BMI, for the primary outcome (M/I) and change in SBP, change in BMI, and change in M/I for the secondary outcomes (vascular markers). We also performed subgroup analysis for M/I stratified by BMI category (lean and obese). Significance was based on an α level of 0.05.
RESULTS
Aortic Stiffness and WSS in Youth With and Without T1DM
Clinical and MRI parameters of participants with T1DM and nondiabetic control participants are summarized in Table 1 . The groups were similar in age (P=0.10) and sex distribution (P=0.53). Although the BMI z score was not different between groups, the BMI percentile was slightly higher in the T1DM group; therefore, comparisons of the baseline MRI measures were controlled for BMI percentile and for the predetermined variables of age and sex. Participants with diabetes mellitus had significantly elevated WSS MAX ( Figure 1A ) and WSS TA (Figure 1B) in both the AA and DA. Youth with T1DM also demonstrated greater PWV in both aortic segments, indicating increased vascular stiffness ( Figure 1C) . Similarly, relative area change was significantly lower in the AA and DA in youth with T1DM ( Figure 1D ), indicating decreased central aortic distensibility.
Baseline Characteristics of Youth With T1DM Randomized Into the Clinical Trial
A CONSORT (Consolidated Standards of Reporting Trials) diagram depicting the randomization and followup visit sample sizes is shown in Figure 2 . The baseline characteristics of the youth with T1DM randomized into the clinical trial stratified by treatment group (placebo versus metformin) are shown in Table 2 . Participants assigned to the placebo versus metformin group were similar in age, T1DM duration, sex distribution, pubertal status, and ethnicity. HbA 1c , systolic and diastolic BP, total cholesterol, HDL-C, LDL-C, triglycerides, total daily insulin dose, M/I per 1 kg, and M/I per 1 lean kg were also similar across the 2 treatment groups at baseline. Figure 3A ) and remained significant after adjustment for sex, pubertal status, and change in BMI (7.4±9.6 Figure 3B) , and both remained significant after adjustment for sex, pubertal status, and change in BMI (P=0.03 for both M/I per 1 kg and M/I per 1 lean kg). 
Primary Outcome
Secondary Outcomes
Safety Data
Of the 48 randomized participants, only 3 participants (6%) did not finish the study protocol. Medication adherence was 93% in the metformin group versus 93% in the placebo group at 6 weeks (P=NS) and 97% in metformin group versus 91% in placebo group at 12 weeks (P=NS). There were no severe adverse events. Adverse events included only minor gastrointestinal side effects (nausea, diarrhea, reduced appetite, stomach pain), which were reported in 10 participants in the metformin group (40%) compared with 2 participants in the placebo group (8%; P<0.01). De-escalation in metformin dose was applied in 3 participants (12%), but all participants tolerated at least 1000 mg metformin per day. There were no significant changes Data are presented as mean±SD unless otherwise noted. AA indicates ascending aorta; cIMT, carotid intima-media thickness; DA, descending aorta; DBP, diastolic blood pressure; GIR, glucose infusion rate; HbA 1c , glycohemoglobin; HDL-C, high-density lipoprotein cholesterol; I, steady-state insulin; LDL-C, low-density lipoprotein cholesterol; M, steady-state glucose infusion rate; NHW, non-Hispanic white; PWV, pulse wave velocity; RAC, relative area change; SBP, systolic blood pressure; TDI, total daily insulin dose; Total-C, total cholesterol; WSS MAX , maximal wall shear stress; and WSS TA , time-averaged wall shear stress.
*Median, 25th to 75th percentile.
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between groups in hemoglobin, alanine aminotransferase, aspartate aminotransferase, or serum creatinine (data not shown).
DISCUSSION
Our T1DM cohort demonstrated vascular dysfunction compared with control participants of similar age, BMI, and sex distribution, and as in our previous studies, adolescents with T1DM had lower insulin sensitivity measured by hyperinsulinemic euglycemic clamp than our previous cohorts of nondiabetic control participants. 4, 5, 9 The primary finding of our current randomized, doubleblinded, controlled trial is that metformin improves directly measured insulin sensitivity. In addition, we demonstrated that metformin reduces weight, BMI, and fat mass and improves measures of aortic and carotid vascular health over 3 months. The improvement in insulin sensitivity was not limited to obese participants and was significant when assessing both per 1 kg of body weight and per 1 kg of fat-free mass. This is the first report demonstrating improvement in insulin sensitivity by the gold-standard hyperinsulinemic euglycemic clamp technique with metformin versus placebo in lean and obese youth with T1DM. In addition, to the best of our knowledge, no other pediatric or adult studies have investigated the impact of metformin therapy on aortic WSS or aortic stiffness. T1DM increases CVD risk 4-to 8-fold, 31 yet there has been a lack of progress in the management of macrovascular complications. Moreover, obesity is now increasing in youth with T1DM, 32 further augmenting CVD risk. Although overt CVD is rare until adulthood, precursors of CVD are increasingly documented in youth with T1DM. For example, youth with T1DM have evidence of a more atherogenic LDL-C and HDL-C distribution, 9 peripheral arterial stiffness, 17,33 elevated BP, 2 increased aortic intima-media thickness 34 and cIMT, 35 endothelial dysfunction, 4,7 diastolic dysfunction, 36 left ventricular hypertrophy, 4 reduced cardiac strain, 8 and lower Vo 2 peak. 4 Accordingly, to reduce CVD risk, it may be beneficial to begin intervention in childhood. Although glycemic control is important to CVD risk, <21% of adolescents currently are able to meet glycemic control guidelines. 37 Furthermore, the recent randomized, placebo-controlled AdDIT study examined the impact of the traditional adjunctive therapies, angiotensin-converting enzyme inhibitors and statins, on CVD risk over 2 to 4 years in 443 adolescents with T1DM. Statins lowered LDL-C and triglycerides and lowered HDL-C; however, neither angiotensin-converting enzyme inhibitors nor statins improved urinary albumin excretion, cIMT, high-sensitivity C-reactive protein, asymmetrical dimethylarginine, glomerular filtration rate, or retinopathy. 3 Therefore, novel approaches to CVD risk reduction in T1DM are needed, especially in youth. Here, we demonstrate improvement in central aortic stiffness and WSS, as well as cIMT, after shortterm metformin therapy.
IR is an increasingly recognized component of T1DM 4, 6, 38 and relates to CVD development. 13 IR in T1DM is not caused by obesity alone; normal-weight youth and adults with T1DM are both significantly insulin resistant compared with well-matched nondiabetic control participants. 4, 6, 11, 38 IR in youth with T1DM relates to markers of increased CVD risk, including reduced Circulation. 4 forearm blood flow, 4 BP, total cholesterol, high sensitivity C-reactive protein, 11 and a more atherogenic lipoprotein profile. 9 Moreover, in adults with T1DM, insulin sensitivity, not HbA 1c , relates to markers of CVD risk, including a more atherogenic lipoprotein profile 10 and the presence, extent, 6 and progression of coronary artery calcification and albuminuria, 12 and predicts definitive coronary artery disease end points (angiographic stenosis, revascularization, Q waves, nonfatal myocardial infarction, and coronary artery disease death) 13 . In earlier studies, cohorts showed a relationship between insulin sensitivity and HbA 1c , 38, 39 whereas newer data in youth and adults using modern insulin analogs and stricter glycemic control show no relationship between insulin sensitivity and either continuous glucose monitoring-or HbA 1c -assessed hyperglycemia 4, 6, 28 . Thus, treatments that target IR in T1DM hold promise as a novel method of preventing CVD.
We assessed aortic PWV and relative area change by phase-contrast-MRI and found significant arterial stiffness and reduced distensibility in both the AA and DA in adolescents with T1DM compared with normal control participants. Furthermore, we observed significantly elevated shear forces in the same aortic segments, which are known to be responsible for triggering endothelial signaling cascades and remodeling of the systemic vasculature, 40 suggesting that flow hemodynamics may contribute to accelerated vasculopathy in T1DM. Endothelial cells in the AA have different responsiveness to shear abnormalities than those at the level of the DA or thoraco-abdominal aorta, 41 demonstrating the importance of assessing segment-specific aortic health, as we did in the present study. Our findings are supported by Samyn et al, 42 who described reduced distensibility and elevated WSS derived by computational fluid dynamic simulation in youth with T1DM. However, our phasecontrast MRI approach has advantages over computational fluid dynamics, including the well-accepted spatial-temporal resolution associated with phase-contrast MRI imaging, and is a directly measured approach that avoids the anatomic and flow hemodynamic assumptions inherent in computational modeling techniques. Furthermore, we found improvements in the AA PWV and WSS, as well as cIMT, with metformin, showing the potential beneficial impact of metformin on CVD in T1DM and supporting the link between CVD and IR in T1DM. Metformin is the only oral medication approved for pediatric use in T2DM and remains the most widely 
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prescribed insulin-sensitizing agent. The effects of metformin in T2DM are incompletely understood but are likely mediated by mechanisms including decreasing hepatic glucose output and increasing glucose disposal in myocytes, 43 its more recently recognized gastrointestinal effects, 44, 45 and direct impacts on the heart, endothelium, and vasculature. 4, 46 The UKPDS trial (UK Prospective Diabetes Study) demonstrated cardiovascular benefits with metformin in adults with T2DM. 22 However, a recent meta-analysis of randomized controlled trials in adults with T2DM demonstrated that although all CVD outcomes except stroke favored metformin, none achieved statistical significance because of the limited number of metformin studies with CVD 47 Because the phenotype of IR in T1DM differs considerably from the metabolic syndrome phenotype of T2DM, 4 it is not clear whether metformin would have similar effects in T1DM as in T2DM, hence the need for the current study.
The data on the effects of metformin in T1DM vary somewhat, but the majority of studies, including our 2 larger studies of the impact of metformin on glycemic control in youth with T1DM 23, 24 and a Cochrane Systematic Review, 48 demonstrate that metformin lowers BMI and insulin dose in youth with T1DM, implying improved insulin sensitivity, but shows no improvement in HbA 1c . The present study confirms and takes these findings a step further by demonstrating that IR measured by gold-standard hyperinsulinemic euglycemic clamp improves in youth with T1DM with metformin versus placebo, as does body composition by dualenergy x-ray absorptiometry. A smaller study in Swedish adolescents in the 1990s assessed insulin sensitivity with metformin use in T1DM but was not powered to compare effects between the metformin and placebo groups. 30 Moreover, the Swedish cohort's inclusion criteria required both a HbA 1c >64 mmol/mol and high insulin requirements, limiting generalizability, and the insulin sensitivity measurement was nonstandard, with an inadequate clamp insulin dose to suppress hepatic glucose output in adolescents and an inadequate clamp insulin infusion time to achieve steady state.
Existing T1DM studies of metformin with CVD outcomes are sparse with inconsistent results. Recently published data from the REMOVAL study (Reducing With Metformin Vascular Adverse Lesions in Type 1 Diabetes) of adults with T1DM did not show a reduction in the primary outcome of progression of mean cIMT but did show significant improvement in maximal cIMT, LDL-C, weight, and estimated glomerular filtration rate. 49 In contrast, a randomized controlled trial by Anderson et al 50 found no significant effect of metformin on mean cIMT in youth (age, 8-18 years) but observed improvement in glyceryl trinitrate-mediated dilatation, indicating improved vascular smooth muscle function. A potential explanation for the differences in cIMT findings in this latter study is the inclusion of 8-to 11-year-olds; younger and prepubertal youth are less likely to have measurable baseline abnormalities in cIMT.
There are important strengths and limitations of our study. First, this carefully designed clinical trial included both normal-weight and overweight/obese participants with T1DM, allowing subanalysis in the normal-weight group. Second, we controlled for the acute impact of diet and physical activity and performed an overnight admission to control acute glycemia and to limit the impact of these variables on insulin sensitivity and vascular measures. Third, we used the gold-standard hyperinsulinemic euglycemic technique to directly measure whole-body insulin sensitivity, dual-energy x-ray absorptiometry to measure body composition, and aortic phase-contrast MRI to assess central aortic health, in addition to more traditional measures of vascular health, including brachial distensibility and cIMT. Moreover, our participant adherence to metformin and visit attendance was excellent. Limitations of this study include the fact that our results may not be applicable to prepubertal youth and that treatment duration was limited to 3 months. In addition, our institution obtained a new MRI scanner during the study, and during the replacement process, MRIs were unavailable. Thus, our MRI sample size was smaller than our other outcomes, a potential explanation for the lack of significant response to metformin in the DA segments. In addition, because our control group was a convenience sample of youth undergoing the identical MRI protocol for another study, we lack the other study outcomes in these participants. Hypoglycemia and marked hyperglycemia were avoided throughout all assessments, but we lacked a measure such as continuous glucose monitoring to repeatedly monitor blood sugars during vascular assessments. Finally, not all girls were studied in the traditionally defined follicular phase because adolescents often have anovulatory, irregular periods in the first 2 years after menarche. However, because girls with anovulatory cycles remain in a pseudofollicular phase, most of our female participants were in a follicular or pseudofollicular phase.
CONCLUSIONS
Youth with T1DM have reduced insulin sensitivity, reduced aortic stiffness, reduced central aortic distensibility, elevated WSS, and increased cIMT compared with normoglycemic peers of a similar age. Metformin therapy for 3 months improved each of these abnormalities, in addition to improving BMI and fat mass. Furthermore, the impact of metformin on insulin sensitivity was not limited to overweight youth with T1DM. IR is an important contributor to CVD disease in T1DM, and metformin may hold promise in reducing CVD risk. Future directions include evaluating the impact of metformin on renal, cardiac, mitochondrial, and exercise function as additional markers of CVD, as well as longer-term trials assessing CVD outcomes.
